Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Xinhua Pharmaceutical (000756): API price increases, performance increases, performance is flexible, specialty formulation CMO lays the foundation for long-term growth
Xinhua Pharmaceutical (000756) Dynamic Analysis: The sharp rise in the volume and price of ibuprofen brings performance elasticity, the international strategy is progressing in an orderly manner, and valuations are expected to increase
Xinhua Pharmaceutical (000756): A Year of Accelerated Transformation of Leading Antipyretic and Analgesic APIs to CMO
Xinhua Pharmaceutical (000756): Performance meets expectations, and consistent evaluations have been harvested one after another
Xinhua Pharmaceutical (000756) in-depth Research report: defense value highlights steadfast and enterprising in the future
Xinhua Pharmaceutical (000756): Revenue continues to grow, gross margin increases further
Xinhua Pharmaceutical (000756): the performance is in line with the expected volume and price of raw materials.
Xinhua Pharmaceutical (000756) Review: The publication of draft stock options bundles benefits the long term
Xinhua Pharmaceutical (000756) report comments: performance is slightly lower than expected consistency evaluation is progressing smoothly
Xinhua Pharmaceutical (000756) Annual report comments: performance growth is in line with expectations and wait for the change to continue to deepen
Xinhua Pharmaceutical (000756) Annual Report Review: Q4 Performance Growth Rate Recovers, Consistency Evaluation Ushers in Harvest Period
Xinhua Pharmaceutical (000756): High performance growth and investment value highlighted
新华制药(000756)重大事项点评:2017年业绩略低于预期 内生储备为后续增长奠定基础
新华制药(000756)事件点评:原料药景气提升 业绩高增长
新华制药(000756):业绩持续高增长长期看好公司发展
新华制药(000756)动态跟踪报告:Q4业绩恢复高增长 制剂一致性评价值得期待
新华制药(000756)深度研究:一体化仿制药企业 受益于行业供给侧改革
新华制药(000756)投资价值分析报告:产业价值多维度重估 制剂和原料药齐升
新华制药(000756)三季报点评:收入持续增长土地收益增厚业绩
No Data
No Data